Table 3.
Association between CLDN18 status and the other biomarkers in metastatic tumours (NS = not significant)
| Biomarker | CLDN18 negative (%) | CLDN18 positive (%) | p |
|---|---|---|---|
| EBER | NE | ||
| Positive | 0 (0.0) | 0 (0.0) | |
| Negative | 92 (69.7) | 40 (30.3) | |
| p53 | NS | ||
| Aberrant | 30 (75.0) | 10 (25.0) | |
| Normal | 56 (70.9) | 23 (29.1) | |
| p16 | NS | ||
| Positive | 41 (71.9) | 26 (28.1) | |
| Negative | 42 (67.7) | 19 (32.3) | |
| MMR | NS | ||
| Deficient | 13 (68.4) | 6 (31.6) | |
| Proficient | 75 (75.0) | 25 (25.0) | |
| E-cadherin | NS | ||
| Positive | 75 (69.4) | 33 (30.6) | |
| Negative | 12 (70.6) | 5 (29.4) | |
| HER2 | NE | ||
| Amplified | 0 (0.0) | 0 (0.0) | |
| Not amplified | 90 (71.4) | 36 (28.6) |
CLDN18 Claudin-18; NE not evaluable